Browse studies

Find your next paid study

5 recruiting studies matching your filters

MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolum…

B-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMyelodysplastic Syndrome+16 more

Estimated

~$10 – $6,250

Mayo ClinicNCT03017820

Phase 2

A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or d…

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT04508790

Phase 1

Phase 1 Trial of 111Indium/225Actinium-DOTA-Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma

This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab a…

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT05363111

Phase 1

Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CS1+ Multiple Myeloma

This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1…

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT03710421

Observational

Improving Host Factors in Patients With Monoclonal Gammopathies and Other Hematologic Disorders

This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions …

Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma+1 more

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT05312255